Elsewhere in this Drug Review Profile, the Pink Sheet examines how Coherus BioSciences, Inc. and Bioeq IP AG provided adequate scientific justification to support an interchangeability determination for Cimerli (ranibizumab-eqrn), a biosimilar to Genentech, Inc.’s macular degeneration drug Lucentis. (Also see "Coherus Biosimilar Used ‘Scientific Justification’ To Skip Switch Study, Still Get Interchangeability With Lucentis" - Pink Sheet, 1 September, 2022.)
This Drug Review Profile also looks at the different expectations of the US Food and Drug Administration and European Medicines Agency for Lucentis biosimilar development programs, including Samsung...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?